Alphatec Holdings, Inc. (NASDAQ:ATEC) General Counsel Tyson Eliot Marshall Sells 12,878 Shares

Key Points

• Tyson Eliot Marshall, the General Counsel of Alphatec Holdings, sold 12,878 shares at $12.00 each, totaling $154,536, reducing his ownership by 2.74% to 456,423 shares.
• Alphatec reported a $0.02 earnings per share for the last quarter, surpassing estimates and achieving 27.5% year-over-year revenue growth.
• Recent institutional investments in Alphatec have increased significantly, with key investors boosting their stakes, indicating strong confidence in the company's future.

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) General Counsel Tyson Eliot Marshall sold 12,878 shares of the business's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $12.00, for a total value of $154,536.00. Following the completion of the sale, the general counsel owned 456,423 shares in the company, valued at approximately $5,477,076. This trade represents a 2.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Tyson Eliot Marshall also recently made the following trade(s):

• On Tuesday, August 5th, Tyson Eliot Marshall sold 18,092 shares of Alphatec stock. The shares were sold at an average price of $14.91, for a total value of $269,751.72.
• On Thursday, July 10th, Tyson Eliot Marshall sold 1,500 shares of Alphatec stock. The shares were sold at an average price of $12.00, for a total value of $18,000.00.

Alphatec Stock Performance

Shares of Alphatec stock traded down $0.30 on Thursday, hitting $14.90. The stock had a trading volume of 4,026,655 shares, compared to its average volume of 2,076,670. The company has a quick ratio of 1.77, a current ratio of 2.88 and a debt-to-equity ratio of 23.22. The stock has a market cap of $2.20 billion, a price-to-earnings ratio of -13.19 and a beta of 1.05. The business's 50 day moving average is $11.53 and its two-hundred day moving average is $11.23. Alphatec Holdings, Inc. has a twelve month low of $4.88 and a twelve month high of $15.46.

Alphatec (NASDAQ:ATEC - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The medical technology company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.08. The business had revenue of $185.54 million during the quarter, compared to analysts' expectations of $178.85 million. Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 24.33%. The firm's revenue for the quarter was up 27.5% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.29) earnings per share. Analysts forecast that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Institutional Investors Weigh In On Alphatec

Institutional investors have recently made changes to their positions in the stock. Wealth Enhancement Advisory Services LLC lifted its stake in Alphatec by 301.0% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 59,987 shares of the medical technology company's stock worth $608,000 after purchasing an additional 45,027 shares during the last quarter. GAMMA Investing LLC lifted its stake in Alphatec by 38,433.3% during the first quarter. GAMMA Investing LLC now owns 2,312 shares of the medical technology company's stock worth $228,000 after purchasing an additional 2,306 shares during the last quarter. SG Americas Securities LLC lifted its stake in Alphatec by 28.3% during the first quarter. SG Americas Securities LLC now owns 56,927 shares of the medical technology company's stock worth $577,000 after purchasing an additional 12,553 shares during the last quarter. Oppenheimer Asset Management Inc. lifted its stake in shares of Alphatec by 13.4% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 13,144 shares of the medical technology company's stock valued at $133,000 after acquiring an additional 1,552 shares during the last quarter. Finally, Rhumbline Advisers lifted its stake in shares of Alphatec by 6.9% in the 1st quarter. Rhumbline Advisers now owns 148,749 shares of the medical technology company's stock valued at $1,508,000 after acquiring an additional 9,661 shares during the last quarter. 66.35% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on ATEC shares. Barclays reaffirmed an "overweight" rating and issued a $22.00 target price (up previously from $21.00) on shares of Alphatec in a research report on Monday. HC Wainwright reissued a "buy" rating and set a $20.00 price target on shares of Alphatec in a research report on Monday, April 14th. Canaccord Genuity Group reissued a "buy" rating and set a $20.00 price target on shares of Alphatec in a research report on Friday, August 1st. Piper Sandler reaffirmed an "overweight" rating and issued a $15.00 target price (up previously from $13.00) on shares of Alphatec in a research report on Friday, May 2nd. Finally, Lake Street Capital raised Alphatec to a "buy" rating and set a $18.00 target price on the stock in a research report on Monday, June 16th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, Alphatec has an average rating of "Moderate Buy" and an average target price of $18.50.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.